Bio Innovation Conference | Conference Agenda
10
page-template,page-template-full_width,page-template-full_width-php,page,page-id-10,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-17.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive
 

Conference Agenda

october 7, 2019 •  bethesda north marriott hotel & conference center

    Monday, October 7, 2019

    7:30 am

    Registration Open | Exhibit Hall Open | Breakfast and Networking

    7:30 am-9:30 am

    BIO One-on-One Partnering Meetings

    8:30 am-8:40 am

    Welcome and Opening Remarks

    Remarks by:
    Martin Rosendale, Chief Executive Officer, Maryland Life Sciences
    Kelly Schulz, Secretary, Maryland Department of Commerce
    Jeff Galvin, Chief Executive Officer and Founder, American Gene Technologies

    8:45 am-9:45 am

    (concurrent panel sessions)

    SESSION A

    Track 1

    Poised for Disruptive Innovation: Maryland’s Rising Cell & Gene Therapy Industry

    What is the current state of affairs for cell and gene therapy companies in Maryland? What keeps these companies here and how are they able to recruit their executive teams into Maryland? How do we make Maryland more attractive to this industry and what resources are available here? This discussion will address these questions while panelists examine the benefits and challenges of partnering in this region and the aspects of cell and gene therapy that are likely to grow over the next decade.

    Moderator:
    Jon Rowley, Ph.D., Founder and Chief Product Officer, RoosterBio

    Panelists:
    Emily English, Ph.D., Chief Executive Officer, Gemstone Biotherapeutics
    Murat Kalayoglu, M.D., Ph.D., MBA, President and Chief Executive Officer, Cartesian Therapeutics
    Kimberly Noonan, Ph.D., Founder, Executive Vice President and Chief Scientific Officer, WindMIL Therapeutics
    William Rust, Ph.D., Chief Executive Officer and Co-Founder, Seraxis

    Track 2

    Alternative Funding Options for Launching Your Company

    This discussion will focus on creative, unique, Maryland-specific opportunities for obtaining startup capital for your company and preparing yourself for venture funding. Panelists will discuss the Maryland Biotechnology Investment Incentive Tax Credit (MBIITC), Maryland Industrial Partnerships (MIPS), Small Business Innovation Research (SBIR) and other options to put your company in a position to attract institutional investments.

    Moderator:
    Jeff Galvin, Chief Executive Officer and Founder, American Gene Technologies

    Panelists:
    Henry Ahn, SBIR/STTR Program Director, National Science Foundation
    Judy Costello, Managing Director, Economic Development, BioHealth Innovation
    Joseph Naft, Director, Maryland Industrial Partnerships (MIPS) Program
    Paul Silber, Founding Principal, Blu Venture Investors

    10:00 am – 11:00 am

    Keynote Address
    Hopes for a Cure – Gene Therapy for Sickle Cell Anemia

    In his keynote address, Dr. Tisdale will address the importance of medical innovation and new advances in gene therapy, as well as the new curative therapy for sickle cell anemia and the work the National Institutes of Heath is doing to cure the disease.

    Sponsored by:

    Remarks by:
    Kelly Martin, Vice President, Business Strategies, BIO
    Doug Doerfler, President and Chief Executive Officer, MaxCyte

    Keynote Speaker:
    John Tisdale, M.D., Chief, Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health

    11:15 am-12:15 pm

    (concurrent panel sessions)

    SESSION B

    Track 1

    Cell and Gene Therapy – How We Successfully Enable Our Future

    An intimate, up to the minute, opportunity to discuss the cell and gene therapy landscape with the industry leaders.  Our fireside chat will include:

    • How far the field has come
    • Recent clinical progress and current commercial challenges
    • What’s ahead for therapeutic developers
    • Maryland’s growing role in bringing cures to patients.

    Moderator:
    Brad Stewart, Chief Executive Officer, Immunology Partners

    Panelists:
    Doug Doerfler, President and Chief Executive Officer, MaxCyte
    Lyndsey Scull, Vice President, Communications, Alliance for Regenerative Medicine

    Track 2

    Employment Opportunities Fulfilled

    The demand for life sciences job skills is growing rapidly in this region. Our roundtables will discuss opportunities and challenges while determining actions which can be taken to ensure workforce readiness and availability for the short and long-term.

    Moderators:
    Sarah Sheppard, Director of Education and Workforce, Office of Strategic Industries and Entrepreneurship, Maryland Department of Commerce

    Roundtable Discussion Leaders:
    Shiva Fritsch, Senior Vice President of Human Resources, REGENXBIO
    Brian Gaines, Chief Executive Officer, Learning Undefeated
    Joseph Sanchez, Ph.D., Associate Director of Learning and Talent Development, AstraZeneca Biologics

    12:15 pm-1:30 pm

     

    Networking Lunch in the Exhibit Hall

    Sponsored by

    11:30 am-4:00 pm

    Bio One-on-One Partnering Meetings

    1:30 pm-2:30 pm

    (concurrent panel sessions)

    SESSION C

    Track 1

    Novel Therapies, Regulatory Realities

    During this session, a panel of regulatory experts will discuss key regulatory challenges and opportunities that companies developing novel therapies commonly fail to anticipate or leverage fully at each stage of a product’s life cycle.

    Moderator:
    Michael Druckman, Partner, Washington, D.C., Hogan Lovells

    Panelists:
    Julia Barrett, M.D., MPH, Senior Clinical Consultant, Biologics Consulting
    David Feigal, M.D., MPH, Partner, NDA Partners
    Randy Prebula, Partner, Washington, D.C., Hogan Lovells

    Track 2

    Strategic Market Planning for Capital and Commercialization

    Experts discuss key considerations and timing for market assessments to drive strategic partnering options and optimized commercial launch success.

    Sponsored by

    Moderator:
    Steven Walker, Chief Business Officer and Commercial Strategist, Biologics Consulting

    Panelists:
    Brian Abraham, Director, Market Access, Life Sciences, BDO
    Luis Gutierrez, Past President, Commercialization Services, Covance
    Ram Palanki, Pharm.D., Senior Vice President of Commercial Strategy and Operations, REGENXBIO
    Tyrell Rivers, Ph.D., Executive Director of Corporate Development, AstraZeneca

    2:45 pm-3:45 pm

    (concurrent panel sessions)

    SESSION D

    Track 1

    New Frontiers of Biomanufacturing

    As Maryland’s cell and gene therapy industry continues to grow, companies are continuously improving the quality and value of their life-saving products. Industry leaders will discuss the evolution of the manufacturing process, generating new product innovations, ongoing challenges and what the future holds for this sector.

    Sponsored by

    Moderator:
    John Walker, Manufacturers Extension Partnership Liaison, NIIMBL

    Panelists:
    Jeffrey Hung, Ph.D., Chief Commercial Officer, Vigene Biosciences
    Robert Lindblad, M.D., Chief Medical Officer, Emmes
    Christopher McDonald, Vice President of Manufacturing, Kite Pharma
    Jon Rowley, Ph.D., Founder and Chief Product Officer, RoosterBio
    Aaron Vernon, Vice President, Engineering and Supply Chain, Autolus

    Track 2

    Past Seed Stage to the Last Mile

    Now that your company is beyond early stage fundraising, how do you attract venture funding? In this discussion, hear from panelists from MRL Ventures Fund and Camden Partners on how they look at potential funding opportunities, as well as an executive who has gone all the way to IPO.

    Sponsored by

    Moderator:
    Linda Segal, Principal, The McCormick Group

    Panelists:
    Subhendu Basu, Ph.D., Chief Operating Officer, Adaptive Phage Therapeutics
    Diana Bernstein, Ph.D., Senior Associate, MRL Ventures
    Pete Buzy, President, Paragon Gene Therapy, Catalent Biologics
    R. Jacob Vogelstein, Ph.D., General Partner, Camden Partners

    4:00 pm-5:00 pm

    Keynote Address

    Remarks by:
    Marc Elrich, Montgomery County Executive
    Nicole Palya Wood, Senior Director of State Advocacy, PhRMA

    Keynote speaker:
    Michelle McMurry-Heath, M.D., Ph.D., Vice President, External Innovation, Global Leader for Regulatory Science, and Executive Director of Scientific Partnerships for JLABS @ Washington, DC

    5:00 pm-6:00 pm

    Cocktail Reception

    Brought to you by Platinum Sponsor

    STAY INFORMED. Join our mailing list to receive our email newsletter.